We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Endo Grows Generics Footprint with $8 Billion Purchase of Par
Endo Grows Generics Footprint with $8 Billion Purchase of Par
Endo International has agreed to buy Par Pharmaceutical from private equity firm TPG for $8 billion, in a deal the companies say will put them within the top five firms in the U.S. generics market.